In the process of developing functional proteins and research reagents, scientists frequently encounter molecular candidates that perform well in preliminary binding assays but fail during scale-up or structural validation. These failures are primarily driven by underlying biophysical liabilities. Highly hydrophobic patches on the molecular surface, unbalanced charge distributions, and suboptimal framework configurations can drastically reduce solubility. This low solubility rapidly leads to protein aggregation, particularly when the molecule is concentrated for structural studies or long-term storage.
For antibodies and fragment-based binders, aggregation and self-association can reduce the effective monomer concentration, introduce assay-to-assay variability, and in some cases increase non-specific interactions—especially in sensitive immunoassays or cell-based binding readouts. In addition, some molecules become difficult to handle at elevated concentrations due to increased viscosity or poor filterability, which complicates formulation screening and automated workflows.